Tag: cardiogenic shock

impella in preventing heart failure in stemi patients

FDA approves extended duration of use for Impella 5.0 and Impella...

Abiomed has announced an expanded US Food and Drug Administration (FDA) approval for the Impella 5.0 and Impella LD heart pumps premarket approval (PMA)...

Prevalence of multiple organ failure among cardiogenic shock patients has steadily...

Between 2000 and 2014, in the USA, the percentage of patients with acute myocardial infarction cardiogenic shock (AMI-CS) who developed multiple organ failure increased...

Challenges of conducting a randomised clinical trials to prove the impact...

Mechanical circulatory support is frequently used to stabilise patient haemodynamics in desperate situations of circulatory failure to increase and maintain end organ perfusion.1 Of...

Cardiogenic shock patients would benefit the most from reducing contact-to-balloon time

Data from the FITT-STEMI (Feedback intervention and treatment times in ST-segment elevation myocardial infarction) trial indicate that reducing the time between first medical contact...

Haemodynamic support with Impella 2.5 heart pump significantly improves survival when...

  A study published in the Journal of Interventional Cardiology indicates that the use of the Impella 2.5 heart pump (Abiomed) is associated with a...